Low-density lipoprotein: a versatile nanoscale platform for targeted delivery

Dai, Luyao; Li, Shuaijun; Qiu, Hao; Zhou, Ruina; Zhou, Hui; Lei, Wenxi; Kang, Huafeng; Wu, Hao; Li, Yuanpei; Ma, Xiuli

doi:10.1039/d2na00883a

Cited by 4 publications

(3 citation statements)

References 142 publications

(172 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Empty NL (as control) was made by using the identical protocol without the addition of M13, as described above. For the in vitro cellular uptake experiment, NL was labeled with a lipophilic carbocyanine dye (DiL, D282, Fisher Scientific, Waltham, MA, USA) to form DiL-labeled NL (DiL–NL), as has been previously described [ 20 ].…”

Section: Methodsmentioning

confidence: 99%

Prevention of Colitis-Associated Cancer via Oral Administration of M13-Loaded Lipid Nanoparticles

Long,

Alghoul,

Sung

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease, is known to increase the risk of colitis-associated cancer (CAC). CAC has been found to be unresponsive to standard chemotherapy regimens, and the current treatments do not utilize effective small-molecule drugs and colon-targeted delivery systems. Previous studies indicated that the M13–nano-liposome (NL) formulation can effectively target the colon and reshape the gut microbiota in ex vivo cultures, generating altered microbial metabolites that can efficiently prevent chronic UC. In this study, we tested the cancer cell uptake ability of the NL formulation and investigated the potential of the M13–NL formulation to prevent CAC in the azoxymethane (AOM)-exposed IL10−/− mouse model. Our findings demonstrate that oral administration of M13–NL prevents tumor development in AOM-exposed IL10−/− mice, suggesting that M13–NL is a promising oral drug formulation for preventing CAC.

show abstract

Section: Methodsmentioning

confidence: 99%

Prevention of Colitis-Associated Cancer via Oral Administration of M13-Loaded Lipid Nanoparticles

Long,

Alghoul,

Sung

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the exact mechanisms that cause the accumulation of photosensitizers in a given tissue are not yet known [ 26 , 27 ]. The photosensitizer can be delivered and accumulated in cells via the low-density lipoprotein (LDL) receptor pathway [ 28 ], thus making low-density lipoproteins a promising vehicle for targeted drug delivery [ 29 , 30 ]. Among the factors determining the subcellular localization pattern of a given sensitizer are the physicochemical properties of photosensitizers, such as lipophilicity and charge.…”

Section: Pdt Mechanism Of Actionmentioning

confidence: 99%

Photodynamic Therapy and Cardiovascular Diseases

Oskroba,

Bartusik-Aebisher,

Myśliwiec

et al. 2024

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases are the third most common cause of death in the world. The most common are heart attacks and stroke. Cardiovascular diseases are a global problem monitored by many centers, including the World Health Organization (WHO). Atherosclerosis is one aspect that significantly influences the development and management of cardiovascular diseases. Photodynamic therapy (PDT) is one of the therapeutic methods used for various types of inflammatory, cancerous and non-cancer diseases. Currently, it is not practiced very often in the field of cardiology. It is most often practiced and tested experimentally under in vitro experimental conditions. In clinical practice, the use of PDT is still rare. The aim of this review was to characterize the effectiveness of PDT in the treatment of cardiovascular diseases. Additionally, the most frequently used photosensitizers in cardiology are summarized.

show abstract

“…Water-insoluble lipids are carried in the blood in the form of particles known as lipoproteins. Lipoproteins consist of a hydrophobic triglyceride/cholesterol ester core surrounded by a single amphiphilic phospholipid layer with embedded apolipoproteins (Dai et al, 2023). Lipoproteins consisting of lipids and proteins are involved in transporting triglycerides and cholesterol in the blood (Ross & Pawlina, 2011).…”

Section: Introductionmentioning

confidence: 99%

Role of Apolipoproteins in Neurodegenerative Diseases

KAÇAMAK,

ELMAS

2023

Journal of Gazi University Health Sciences Institute

View full text Add to dashboard Cite

Since lipids are insoluble in water, they are carried in the blood as particles called lipoproteins. Lipoproteins consisting of lipids and proteins are multicomponent complexes. The classification of lipoproteins, which are divided into several main groups such as low density lipoprotein (LDL), high density lipoprotein (HDL), very low density lipoprotein (VLDL) and chylomicrons, is based on their density, size, lipid and apolipoprotein content. Apolipoproteins are the protein component of lipoproteins that carry lipids from the blood to various tissues of the body for metabolism and utilisation. Apolipoproteins play an important role in lipid metabolism. They regulate many metabolic enzymes and interact with lipoprotein receptors. Numerous studies have shown that apolipoprotein phenotype, different allelic polymorphism and apolipoprotein gene mutation can affect metabolism and utilisation of blood lipids and consequently trigger the onset and development of atherosclerosis, hyperlipidaemia, cerebrovascular and cardiovascular diseases. Furthermore, apolipoproteins have been associated with neurodegenerative diseases and different apolipoprotein polymorphisms have been evaluated as risk factors or protective agents in different neurodegenerative diseases. This review presents evidence from some studies linking apolipoproteins with Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration disease.

show abstract

Low-density lipoprotein: a versatile nanoscale platform for targeted delivery

Abstract: This review introduces low-density lipoprotein (LDL) delivery systems, summarizes the research status and progress in targeted diagnosis and therapy, and looks forward to the clinical application of LDL as an effective delivery vehicle.

Cited by 4 publications

References 142 publications

Prevention of Colitis-Associated Cancer via Oral Administration of M13-Loaded Lipid Nanoparticles

Prevention of Colitis-Associated Cancer via Oral Administration of M13-Loaded Lipid Nanoparticles

Photodynamic Therapy and Cardiovascular Diseases

Role of Apolipoproteins in Neurodegenerative Diseases

Contact Info

Product

Resources

About